In the U.S alone, almost 21 million GI endoscopies are conducted every year, with colonoscopies making up about 60 per cent of the procedures. Additionally, three million American adults are dealing with inflammatory bowel disease (IBD). According to research by Latham Biopharm Group, the market for severe IBD diagnostics is expected to hit a whopping $1.28 billion globally by 2029.

At the heart of Optiscan’s proprietorial technology is its ability to provide real-time, non-invasive single live cell imaging at a sub-cellular resolution.

By applying the IP to various devices, the company has continued to roll out new products relevant to market demand.

The collaboration deal with Monash University has continued a busy year by the company as it seeks to commercialise its imaging technology across numerous medical disciplines including oral, cervical, surgical, veterinary, pathology and now GI assessments.

Topping the list of achievements, in June Optiscan unveiled its new microscopic InVue medical imaging tool designed to enable surgeons to gain immediate pathology insights in the operating theatre and make on-the-spot decision making, treatment adjustments and undertake precision surgery.

The company has also entered a “know-how” partnership with the globally renowned Mayo Clinic to develop a digital confocal laser endomicroscopic imaging system for use in robotic surgery.

Optiscan appears to be ticking all the right boxes with the market at the moment with the share price riding high, up more than 100 per cent for the year at 16c a share but not before hitting a high of 26c at the start of July.

Sales revenues reported in its September quarterly showed strong signs of improvement too, clocking in at $638,000, its highest level in more than 12 months. With the release of new devices and the promise of entering into numerous other addressable markets in the next year, Optiscan will continue to gain momentum as it continues into the new year.

Is your ASX-listed company doing something interesting? Contact: [email protected]